Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia

Leukemia Research

Volumn 37, Issue 8, 2013, Pages 868-871

  Trifilio, Steven ^a,b   Zhou, Zheng ^a   Mehta, Jayesh ^a   Czerniak, Colleen ^b   Pi, Judy ^b   Greenberg, Deborah ^b   Koslosky, Molly ^b   Pantiru, Mihaela ^c   Altman, Jessica ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c Sacred Heart Hospital   (United States)

Author keywords

Acute leukemia; Daunorubicin; Idarubicin

Indexed keywords

DAUNORUBICIN; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOODSTREAM INFECTION; CARDIOTOXICITY; DRUG FATALITY; FEMALE; HUMAN; INFECTION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SINUS BRADYCARDIA; SINUS TACHYCARDIA; TREATMENT OUTCOME; UNITED STATES;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; DAUNORUBICIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IDARUBICIN; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); REMISSION INDUCTION; YOUNG ADULT;

EID: 84879788734     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.04.009     Document Type: Article

References (16)

1. American Society of Health-System Pharmacist website at. http://www.ashp.org/Drugshortages/Current.
2. Wiernik P.H., Banks P.L., Case D.C., et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood 1992, 79(2):313-319.
3. Lee J.H., Joo Y.D., Kim H., et al. A randomized trial comparing standard versus highdose daunorubicin induction in patients with acute myeloid leukemia. Blood 2011, 118(14):3832-3841.
4. Vogler W.R., Velez-Garcia E., Weiner R.S., et al. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol 1992, 10(7):1103-1111.
5. Berman E., Heller G., Santorsa J., et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 1991, 77(8):1666-1674.
6. Mandelli F., Petti M.C., Ardia A., et al. A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA. Eur J Cancer 1991, 27(6):750-755.
7. Reiffers J., Huguet F., Stoppa A.M., et al. A prospective randomized trial of idarubicin vs. daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55-75. Leukemia 1996, 10(3):389-395.
8. THE AML COLLABORATIVE GROUP A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. Br J Haematol 1998, 103:100-109.
9. Ziogas D.C., Voulgarelis M., Zintzaras E A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly. Clin Ther 2011 Mar, 33(3):254-279.
10. Fernandez H.F., Sun Z., Yao X., et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med 2009, 361(13):1249-1259.
11. Löwenberg B., Ossenkoppele G.J., van Putten W., et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361(13):1235-1248.
12. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia: rationale and important changes. Blood 2009, 114(5):937-951.
13. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of pre-remission and post-remission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000, 96(13):4075-4083.
14. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98(6):1752-1759.
15. Ohtake S., Miyawaki S., Fujita H., et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood 2011, 117(8):2358-2365.
16. Pautas C., Merabet F., Thomas X., et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50-70 years: results of the ALFA-9801 study. J Clin Oncol 2010, 28(February (5)):808-814.